AUTHORS
Scott F. Huntington, MD, MPH, Sophia Li2, Carolina Reyes, PhD3, Parag Nihalani4, Eric Zuk5, Matthew Davis6, Rebecca Straubing7, Matthew J Matasar, MD, MS8
AFFILIATIONS
1 Yale University School of Medicine, New Haven, Connecticut, United States
2 Genentech, Inc., South San Francisco, California, United States
3 Genentech, Inc., South San Francisco, California, United States
4 Genentech, Inc., South San Francisco, California, United States
5 Medicus Economics, Boston, Massachusetts, United States
6 Medicus Economics, Boston, Massachusetts, United States
7 Medicus Economics, Boston, Massachusetts, United States
8 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
ABSTRACT
Background:
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive subtype of non-Hodgkin lymphoma, with a proportion of patients experiencing refractory disease or relapse (R/R) after initial treatment. Treatment options for R/R DLBCL patients have expanded rapidly, including chimeric antigen receptor T-cell therapies (CAR-T) and polatuzumab vedotin (pola) in second-line (2L) since 2022, and bispecific antibodies (BsAb) in third-line or later (3L+) since 2023. In this study, we examine patient characteristics and changes in treatment patterns over time for Medicare patients initiating 2L+ treatment for DLBCL.
Methods:
This retrospective study used 100% Medicare fee-for-service claims data (2019–2025). Patients included had ≥1 inpatient or ≥2 outpatient DLBCL diagnoses based on International Classification of Diseases, 10th revision, Clinical Modification codes, were aged 66 years or older at DLBCL diagnosis date, initiated ≥2 lines of DLBCL therapy, and continuously enrolled in Medicare Parts A/B (without Part C) for ≥12 months preceding DLBCL diagnosis with no DLBCL diagnosis or treatment, and ≥3 months following initiation of 2L treatment. Patient characteristics were evaluated at 2L initiation for each treatment class and compared to the CAR-T reference group using Welch’s two-sample t-tests reporting unadjusted p-values. The proportions of patients receiving each treatment class in 2L, progressing to 3L treatment, and receiving each treatment class in 3L were characterized overall. Treatment patterns were also stratified by 2L initiation in 2019-2022 vs. 2023-2025 to assess changes in use following the introduction of novel therapies, and 2025 specifically to summarize recent use patterns.
Results:
We identified 6,948 Medicare beneficiaries initiating 2L DLBCL treatment. The cohort was 56% male, 86% Non-Hispanic White, and 79% urban, with a mean age of 77.4 years, and a mean Charlson comorbidity index (CCI) of 3.1. Conventional therapies (chemotherapy, chemoimmunotherapy, anti-CD20 monotherapy) were most common (46.8%), followed by pola-based regimens (16.0%), CAR-T (15.9%) and SCT (6.2%). BsAbs represented 1.9% of the cohort. Mean follow-up time after 2L initiation was 19.9 months; 2,057 patients (29.6%) initiated 3L and 2,519 patients (36.3%) died without initiating 3L. Among patients initiating 2L, observed utilization was higher in recent years (2023-2025) than in earlier years (2019-2022) for CAR-T (22.2% vs 10.0%), pola-based regimens (18.7% vs 13.3%), and BsAbs (4.0% vs 0.0%), and lower for SCT (4.4% vs 7.9%) and conventional therapies (39.3% vs 54.0%). 22.7% of 2L patients utilized CAR-T in 2025. BsAb utilization in 2L was first observed in 2023 and increased yearly to 6.7% of 2L patients in 2025. Mean age at 2L initiation was 74.6 years for CAR-T patients. Compared to CAR-T, mean age was higher for BsAb (79.5, +5.0), pola-based regimens (79.5, +4.9) and conventional therapies (77.6, +3.0), and lower for SCT (71.2, -3.3) (all p<0.0001). Compared to CAR-T (mean CCI: 2.8), the mean CCI was higher for BsAb (3.8, +1.0, p<0.0001), pola-based regimens (3.4, +0.6, p<0.0001) and conventional therapies (3.1, +0.3, p=0.0001), and lower for SCT (2.5, -0.3, p=0.0229). Among patients initiating 3L, observed utilization was higher in 2023-2025 than in 2019-2022 for BsAbs (14.6% vs 0.0%), and lower for CAR-T (23.7% vs 26.1%) and SCT (4.3% vs 13.1%). 22.5% of 3L patients utilized CAR-T in 2025. BsAb utilization in 3L was first observed in 2023 and increased yearly to 19.9% of 3L patients in 2025.
Conclusions:
This study provides a real-world assessment of the shifting treatment landscape for 2L and 3L DLBCL among US Medicare patients, reflecting recent advancements in novel treatment options. Patients initiating 2L in recent years more frequently received BsAbs, CAR-Ts, and pola-based regimens while use of SCT and conventional therapies decreased. Despite increasing use of novel treatments, many patients still receive conventional therapies in 2L. CAR-T and SCT were predominantly used among patients who were younger and had less comorbidity burden, relative to BsAbs, pola-based and conventional regimens. Emerging therapies like BsAbs and pola appear to be addressing a treatment gap for patients for whom cellular therapies like CAR-T or SCT may be less suitable or accessible. Future work is needed to evaluate whether this shift in treatment patterns is associated with improved clinical outcomes.
DISCLOSURES
Scott F. Huntington, MD, MPH: AstraZeneca - Honoraria; Genentech - Honoraria; BeOne - Research Funding; Nurix Therapeutics - Research Funding; AbbVie - Research Funding; Merck & Co., Inc. - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)